Company Overview of Q Therapeutics, Inc.
Q Therapeutics, Inc., a development stage company, engages in the development of human cell-based therapies for the treatment of degenerative diseases of the brain and spinal cord. It develops Q-Cells that are healthy human glial cells intended for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, transverse myelitis, traumatic spinal cord injury, and Parkinson’s disease, as well as for Alzheimer’s disease, traumatic brain injury, cerebral palsy, stroke, and Leukodystrophies and central nervous system storage diseases. The company was formerly known as Q Holdings, Inc. and changed its name to Q Therapeutics, Inc. in December 2012. Q Therapeutics, Inc. is headquartered in Sa...
615 Arapeen Drive
Salt Lake City, UT 84108
Key Executives for Q Therapeutics, Inc.
Scientific Co-Founder and Chief Scientific Consultant
Senior Director of Research & Development
Compensation as of Fiscal Year 2013.
Q Therapeutics, Inc. Key Developments
Q Therapeutics, Inc. Receives Orphan Drug Designation from U.S. Food & Drug Administration for Q-Cells for Treatment of ALS
Nov 21 13
Q Therapeutics, Inc. announced that the U.S. Food & Drug Administration (FDA) has granted the company Orphan Drug Designation for its Q-Cells product (human glial restricted progenitor cells and their progeny), for the treatment of Amyotrophic Lateral Sclerosis (ALS). Granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 patients in the United States, Orphan Drug Designation enables companies to benefit from financial incentives from the FDA including seven years of market exclusivity after product marketing clearance, access to federal grant funding opportunities to defray clinical trial costs, as well as assistance with clinical protocols and federal tax credits. These incentives are meant to encourage companies to develop products for treatment of orphan diseases. The potential for seven years of market exclusivity protection after product launch augments Q-Cells proprietary position. ALS, also known as Lou Gehrig's Disease, occurs throughout the world with no racial, ethnic or socioeconomic boundaries. According to the ALS Association, approximately 5,600 people are diagnosed with ALS in the United States each year. It is estimated that as many as 30,000 Americans may have the disease at any given time. ALS is notoriously difficult to treat. Most ALS patients die two to five years after diagnosis, as no effective therapies exist.
Q Holdings, Inc. Appoints Diane Jorkasky to Board of Directors
Mar 14 13
Q Holdings, Inc. announced the appointment of Diane Jorkasky, M.D., FACP, as an independent member of its board of directors. Dr. Jorkasky will assume the board seat formerly held by Joydeep Goswami, Ph.D., President of Life Technologies, Japan. Dr. Jorkasky is a 25-year veteran of the pharmaceutical industry with experience in Phases 1-4 clinical trials, including protocol development, conduct and reporting; site placement strategy; and regulatory interaction.
Q Holdings, Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 03:30 PM
Jan 12 13
Q Holdings, Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 03:30 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States. Speakers: Deborah A. Eppstein, Chief Executive Officer, President and Director, Steven J. Borst, Chief Financial Officer, Principal Accounting Officer and Vice President of Corporate Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|